CRP and rheumatoid arthritis: We identified six short-term randomised trials (12–52 week duration) evaluating 4 mg/kg or 8 mg/kg tocilizumab in 2891 patients with rheumatoid arthritis (weighted mean age 52·3 years; 19% male; appendix p 28).8, 9, 26, 27, 28, 29 C-reactive protein was the most widely reported inflammation marker and its weighted mean concentration at baseline was 28·2 (SD 1·9) mg/L.